A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes

Not Applicable

Completed

• Conditions: Type 2 Diabetes Treated With Insulin
• Interventions: Device: Standard Therapy plus continuous glucose monitoring (CGM)

• Registration Number: NCT05785832
• Lead Sponsor: Tandem Diabetes Care, Inc.

Brief Summary

A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ technology in adults with type 2 diabetes using basal-bolus insulin therapy.

Detailed Description

A randomized controlled trial (RCT) will evaluate 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology 1.5 in adults with type 2 diabetes age 18 and older using basal-bolus insulin therapy compared with continuation of pre-study insulin delivery plus continuous glucose monitoring (CGM). At least 300 participants will complete the trial at up to 25 clinical sites, across the United States and Canada.

The primary outcome is change in hemoglobin A1c (HbA1c) compared between the intervention and control group. The secondary endpoints will be tested for superiority, with a hierarchical testing approach. Additional outcomes are exploratory.

Study Timeline

• Study First Submitted: 2023-03-14
• Study First Submitted QC: 2023-03-14
• Study First Posted: 2023-03-27
• Study Start: 2023-06-01
• Primary Completion: 2024-09-24
• Study Completion: 2024-09-24
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-02
• Last Update Posted: 2024-10-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 319

Inclusion Criteria

• Age ≥18 years old at time of screening.

• Currently resides in the U.S. or Canada with the ability to complete in-person study visits at one of the participating clinical sites.

• Clinical diagnosis, based on investigator assessment, of type 2 diabetes of at least 6 months duration at time of screening.

• Using basal-bolus insulin therapy with at least one injection containing rapid-acting insulin per day or an insulin pump for at least 3 months prior to enrollment, with no major modification to insulin regime in the last 3 months (mixed insulin with a rapid component is acceptable).

• If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications, dose has been stable for the 3 months prior to screening; and participant is willing to not change the dose unless required for safety purposes.

• Participant willing to not initiate use of any new glucose-lowering medications during the trial.

• Willing to use an approved insulin while using the study pump if assigned to the AID group.

• Willing to not use concentrated insulin above U-100 or inhaled insulin while using the study pump.

• Willing to participate in the study meal and exercise challenges if assigned to the AID group, and have a care partner, trained in hypoglycemia treatment guidelines, to include glucagon use, present during and immediately after the exercise challenges.

• Has the ability to read and understand written English.

• Investigator believes that the participant has the cognitive capacity to provide informed consent.

• Investigator believes that the participant can successfully and safely operate all study devices and is capable of adhering to the protocol and completing the study.

• No medical, psychiatric, or other conditions, or medications being taken that in the investigator's judgement would be a safety concern for participation in the study. This includes considering the potential impact of medical conditions known to be present including cardiovascular, liver, kidney disease, thyroid disease, adrenal disease, malignancies, vision difficulties, active proliferative retinopathy, and other medical conditions; psychiatric conditions including eating disorders; drug or alcohol abuse.

• Participants capable of becoming pregnant must meet one of the following criteria:

  1. has a negative urine pregnancy test and agrees to use one of the accepted contraceptive regimens throughout the entire duration of the trial from screening until last follow-up visit. The following contraceptive measures are considered adequate:

     1. Combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal).
     2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable).
     3. Placement of an intrauterine device or intrauterine hormone-releasing system.
     4. Bilateral tubal occlusion.
     5. Barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository).
     6. Has a vasectomized or sterile partner (where partner is sole partner of subject) and where vasectomy has been confirmed by medical assessment.
     7. Exercises true sexual abstinence. Sexual abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.

     or

  2. Participant is of non-childbearing potential due to menopause with at least one year since last menses or a medical condition confirmed by the investigator.

Exclusion Criteria

• Current use of hybrid closed-loop system.
• Current use of systemic glucocorticoids or anticipated use of glucocorticoids during the RCT (topical or inhaled -ie, non-systemic is acceptable).
• Current use of sulfonylurea or meglitinide medications.
• Current use of hydroxyurea.
• Tape allergy or skin condition that will preclude use of the study pump or CGM.
• Presence of a hemoglobinopathy or other condition that is expected to affect the measurement of HbA1c.
• Pregnant (positive urine hCG), breast feeding, plan to become pregnant in the next 2 months, or sexually active without use of contraception.
• Current participation in another diabetes-related interventional clinical trial.
• Anticipated change of residency or travel for more than 7 days at a time during the study that may, per investigator judgment, interfere with the completion of study visits, contacts, or procedures.
• Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is an investigative site personnel directly affiliated with this study or who is an employee of Tandem Diabetes Care, Inc.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	Standard Therapy plus continuous glucose monitoring (CGM)	Continuation of pre-study basal-bolus insulin delivery method, plus use of study CGM (Dexcom G6).

Primary Outcome Measures

Name	Time	Method
HbA1c	13 weeks	Change in HbA1c (%) from baseline between the intervention and control groups

Secondary Outcome Measures

Name	Time	Method
Coefficient of variation	13 weeks	Change in coefficient of variation mg/dL from baseline, compared between the intervention and control groups
Time in range 70-180 mg/dL	13 weeks	Change in CGM percent time 70-180 mg/dL from baseline, compared between the intervention and control groups
Mean glucose	13 weeks	Change in mean CGM glucose mg/dL from baseline, compared between the intervention and control groups
Time <70 mg/dL	13 weeks	Change in CGM percent time \<70 mg/dL from baseline, compared between the intervention and control groups
Time <54 mg/dL	13 weeks	Change in CGM percent time \<54 mg/dL from baseline, compared between the intervention and control groups
Time >250 mg/dL	13 weeks	Change in CGM percent time \>250 mg/dL from baseline, compared between the intervention and control groups
CGM-measured hypoglycemia events	13 weeks	Change in number of CGM-measured hypoglycemia events (15 or more consecutive minutes \<54 mg/dL) from baseline, compared between the intervention and control groups
Time >180 mg/dL	13 weeks	Change in CGM percent time \>180 mg/dL from baseline, compared between the intervention and control groups
Prolonged hyperglycemia events	13 weeks	Change in number of prolonged hyperglycemia events (\>90 minutes \>300 mg/dL within a 120-minute period) from baseline, compared between the intervention and control groups

Trial Locations

Locations (21)

Hoag Memorial Hospital Presbyterian; 🇺🇸 Newport Beach, California, United States

Emory University School of Medicine; 🇺🇸 Atlanta, Georgia, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

Baltimore VA Medical Center; 🇺🇸 Baltimore, Maryland, United States

SUNY Upstate Medical University; 🇺🇸 Syracuse, New York, United States

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

University of Texas Southwestern; 🇺🇸 Dallas, Texas, United States

UHH Cleveland Medical Center; 🇺🇸 Cleveland, Ohio, United States

Boston Medical Center Corporation; 🇺🇸 Boston, Massachusetts, United States

University of Washington; 🇺🇸 Seattle, Washington, United States

University of Virginia; 🇺🇸 Charlottesville, Virginia, United States

Rocky Mountain Clinical Research; 🇺🇸 Idaho Falls, Idaho, United States

McGill University; 🇨🇦 Montréal, Quebec, Canada

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Henry Ford Health System; 🇺🇸 Detroit, Michigan, United States

Oregon Health & Science University; 🇺🇸 Portland, Oregon, United States

Icahn School of Medicine at Mt. Sinai; 🇺🇸 New York, New York, United States

Texas Diabetes and Endocrinology, P.A.; 🇺🇸 Austin, Texas, United States

Diabetes & Endocrine Treatment Specialists; 🇺🇸 Sandy, Utah, United States

Rainier Clinical Research Center; 🇺🇸 Renton, Washington, United States

Lawson Health Research Institute; 🇨🇦 London, Ontario, Canada